Q1 FY27 results: Revenue up 91% YoY to Rs 227.76 cr, PAT up 95% to Rs 13.17 cr

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+18.8%Reaction day

₹1113.80

prior close

₹1185.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+17.5% vs market

Pharmaceuticals peers, median of 166sector-0.0%+18.8% vs sector

On the reaction day the stock moved 17.5 pts more than Nifty Microcap 250 and 18.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+8.4

10m

+6.2

15m

+9.0

30m

+4.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+18.8+1.3+17.5-0.0+18.8

Next day

+8.6+1.6+7.0+0.2+8.5

+11.7+1.7+10.0+0.4+11.3

+9.8+1.6+8.2+1.0+8.8

+14.5+1.5+13.0+1.2+13.3

+25.4+1.8+23.6+1.0+24.4

+40.1+2.1+38.0+0.5+39.6

15d

—+3.2—-0.0—

—+3.7—+1.7—

—+1.1—+1.1—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fredun Pharmaceuticals posted strong Q1 FY27 results with revenue surging 90.7% YoY to Rs 22,775.55 lakhs (vs Rs 11,940.29 lakhs in Q1 FY26). PAT grew 94.6% to Rs 1,316.81 lakhs (vs Rs 676.58 lakhs). EPS rose to Rs 23.89 from Rs 14.33. Consolidated PAT stood at Rs 1,313.23 lakhs. Auditor R.H. Nisar and Co issued an unmodified limited review report on both standalone and consolidated results.

Likely market impact

Strong double-digit revenue and profit growth with a clean auditor opinion signals robust business momentum for the stock.